Engineering blood vessels by gene and cell therapy

Expert Opinion on Biological Therapy

Volumn 7, Issue 8, 2007, Pages 1183-1191

  Zarbiv, Gabriel ^a   Preis, Meir ^a,b   Ben Yosef, Yaara ^a   Flugelman, Moshe Y ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bypass surgery; Cell therapy; Gene therapy; Tissue engineering; Vascular graft

Indexed keywords

ATHEROSCLEROSIS; BLOOD VESSEL; BLOOD VESSEL GRAFT; BRAIN BLOOD FLOW; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CELL THERAPY; CORONARY ARTERY BLOOD FLOW; GENE THERAPY; HUMAN; LEG BLOOD FLOW; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; TISSUE ENGINEERING;

ANIMALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSELS; CELL TRANSPLANTATION; GENE THERAPY; HUMANS; TISSUE ENGINEERING;

EID: 34548170678     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.8.1183     Document Type: Review

References (103)

1. WHO: The world health report 2004 (2004).
2. GARCIA L: Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J. Endovasc. Ther. (2006) 13(Suppl. 2):II3-II9.
3. STAUDACHER D, FLUGELMAN M: Cell and gene therapies in cardiovascular disease with special focus on the no option patient. Curr. Gene Ther. (2006) 6:609-623.
4. SIMONS M: Angiogenesis: where do we stand now? Circulation (2005) 111:1556-1566.
5. LANGER R, VACANTI J: Tissue engineering. Science (1993) 260(5110):920-926.
6. WEINBERG C, BELL E: A blood vessel model constructed from collagen and cultured vascular cells. Science (1986) 231(4736):397-400.
7. HEDMAN M, HARTIKAINEN J, SYVANNE M et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation (2003) 107:2677-2683.
8. HENRY T, ANNEX B, MCKENDALL G et al.: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation (2003) 107:1359-1365.
9. KASTRUP J, JORGENSEN E, RUCK A et al.: Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris a randomized double-blind placebo-controlled study: the euroinject one trial. J. Am. Coll. Cardiol. (2005) 45:982-988.
10. STAUDACHER D, PREIS M, LEWIS B, GROSSMAN P, FLUGELMAN M: Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol. Ther. (2006) 109:263-273.
11. WANG C, DOBRZYNSKI E, CHAO J, CHAO L: Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am. J. Physiol. Renal Physiol. (2001) 280(6):F964-F971.
12. AKHTER S, SKAER C, KYPSON A et al.: Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc. Natl. Acad. Sci. USA (1997) 94(22):12100-12105.
13. FISCHER L, PREIS M, WEISZ A et al.: Viral vectors for vascular gene therapy. Exp. Clin. Cardiol. (2002) (7):106-112.
14. EDELSTEIN M, ABEDI M, WIXON J, EDELSTEIN R: Gene therapy clinical trials worldwide 1989-2004 - an overview. J. Gene Med. (2004) 6:597-602.
15. ISNER J, VALE P, SYMES J, LOSORDO D: Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ. Res. (2001) 89:389-400.
16. FIELDS R, SOLAN A, MCDONAGH K, NIKLASON L, LAWSON J: Gene therapy in tissue-engineered blood vessels. Tissue Eng. (2003) 9:1281-1287.
17. AMADO L, SCHULERI K, SALIARIS A et al.: Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J. Am. Coll. Cardiol. (2006) 48(10):2116-2124.
18. ASSMUS B, HONOLD J, SCHACHINGER V et al.: Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. (2006) 355(12):1222-1232.
19. SCHACHINGER V, ERBS S, ELSASSER et al.: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. (2006) 355(12):1210-1221.
20. BENGEL F, SCHACHINGER V, DIMMELER S: Cell-based therapies and imaging in cardiology. Eur J. Nucl. Med. Mol. Imaging (2005) 32(Suppl. 2):S404-S416.
21. + cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. (2006) 116(7): 1865-1877.
22. NIZANKOWSKI R, PETRICZEK T, SKOTNICKI A, SZCZEKLIK A: The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardiol. Pol. (2005) 63(4):351-360; discussion 361.
23. LENK K, ADAMS V, LURZ P et al.: Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur. Heart J. (2005) 26(18):1903-1909.
24. TATENO K, MINAMINO T, TOKO H et al.: Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ. Res. (2006) 98(9); 1194-1202.
25. TATEISHI-YUYAMA E, MATSUBARA H, MUROHARA T et al.: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet (2002) 360(9331):427-435.
26. KOBAYASHI K, KONDO T, INOUE N et al.: Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler. Thromb. Vasc. Biol. (2006) 26(7): 1465-1472.
27. SHAH PJ, DURAIRAJ M, GORDON I et al.: Factors affecting patency of internal thoracic artery graft: clinical and angiographic study in 1434 symptomatic patients operated between 1982 and 2002. Eur. J. Cardiothorac. Surg. (2004) 26(1):118-124.
28. SHAH PJ, SEEVANAYAGAM S, ROSALION A et al.: Patency of the radial artery graft: angiographic study in 209 symptomatic patients operated between 1995 and 2002 and review of the current literature. Heart Lung Circ. (2004) 13(4):379-383.
29. LYTLE BW, COSGROVE DM, RATLIFF NB, LOOP FD: Coronary artery bypass grafting with the right gastroepiploic artery. J. Thorac. Cardiovasc. Surg. (1989) 97(6):826-831.
30. KLINKERT P, POST P, BRESLAU P, VAN BOCKEL J: Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur. J. Vasc. Endovasc. Surg. (2004) 27:357-362.
31. KU D, CAULFIELD J, KIRKLIN J: Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation (1991) 83:402-411.
32. PANETTA T, MARIN M, VEITH F et al.: Unsuspected preexisting saphenous vein disease: an unrecognized cause of vein bypass failure. J. Vasc. Surg. (1992) 15:102-110.
33. HUYNH T, ABRAHAM G, MURRAY J et al.: Remodeling of an acellular collagen graft into a physiologically responsive neovessel. Nat. Biotechnol. (1999) 17:1083-1086.
34. VOORHEES AJ, JARETZKI AR, BLAKEMORE A: The use of tubes constructed from vinyon 'n' cloth in bridging arterial defects. Ann. Surg. (1952) 135:332-336.
35. ZDRAHALA RJ: Small caliber vascular grafts. Part I: state of the art. J. Biomater. Appl. (1996) 10(4):309-329.
36. ABBOTT W, GREEN R, MATSUMOTO T et al.: Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. J. Vasc. Surg. (1997) 25:19-28.
37. SOTTIURAI V, YAO J, FLINN W, BATSON R: Intimal hyperplasia and neointima: an ultrastructural analysis of thrombosed grafts in humans. Surgery (1983) 93:809-817.
38. PASIC M, MULLER-GLAUSER W, ODERMATT B et al.: Seeding with omental cells prevents late neointimal hyperplasia in small-diameter Dacron grafts. Circulation (1995) 92(9):2605-2616.
39. GUIDOIN R, CHAKFE N, MAUREL S et al.: Expanded polytetrafluoroethylene arterial prostheses in humans: histopathological study of 298 surgically excised grafts. Biomaterials (1993) 14:678-693.
40. PARSSON H, JUNDZILL W, JONUNG T, THORNE J, NORGREN L: The adhesion of labelled neutrophils on synthetic vascular grafts, an experimental porcine study. Eur. J. Vasc. Surg. (1993) 7:257-262.
41. L'HEREUX N, PAQUET S, LABBE R, GERMAIN L, AUGER F: A completely biological tissue-engineered human blood vessel. FASEB J. (1998) 12:47-56.
42. L'HEUREUX N, DUSSERRE N, KONIG G et al.: Human tissue-engineered blood vessels for adult arterial revascularization. Nat. Med. (2006) 12(3):361-365.
43. PICHAKRON KO, BUI PT, PICKARD BJ et al.: The application of split-thickness skin graft as an autogenous arterial conduit in a goat (Capra hircus) model. Vasc. Endovasc. Surg. (2006) 40(3):213-222.
44. CAMPBELL JH, EFENDY JL, CAMPBELL GR: Novel vascular graft grown within recipient's own peritoneal cavity. Circ. Res. (1999) 85(12):1173- 1178.
45. CHUE WL, CAMPBELL GR, CAPLICE N et al.: Dog peritoneal and pleural cavities as bioreactors to grow autologous vascular grafts. J. Vasc. Surg. (2004) 39(4):859-867.
46. BORSCHEL GH, HUANG YC, CALVE S et al.: Tissue engineering of recellularized small-diameter vascular grafts. Tissue Eng. (2005) 11(5-6):778-786.
47. KIM WG, SEO JW, YANG JH: Comparative analysis of frozen and acellularized vascular xenografts. Int. J. Artif. Organs (2005) 28(8):848-852.
48. SIMIONESCU DT, LU Q, SONG Y et al.: Biocompatibility and remodeling potential of pure arterial elastin and collagen scaffolds. Biomaterials (2006) 27(5):702-713.
49. YOW K, INGRAM J, KOROSSIS S, INGHAM E, HOMER-VANNIASINKAM S: Tissue engineering of vascular conduits. Br. J. Surg. (2006) 93:652-661.
50. ISENBERG B, WILLIAMS C, TRANQUILLO R: Small-diameter artificial arteries engineered in vitro. Circ. Res. (2006) 98:25-35.
51. SCHMIDT C, BAIER J: Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials (2000) 21(22):2215-2231.
52. HERRING M, GARDNER A, GLOVER J: A single-staged technique for seeding vascular grafts with autogenous endothelium. Surgery (1978) 84:498-504.
53. GREISLER H: Interactions at the blood/material interface. Ann. Vasc. Surg. (1990)4:98-103.
54. BUDD J, ALLEN K, HARTLEY G, BELL P: The effect of preformed confluent endothelial cell monolayers on the patency and thrombogenicity of small calibre vascular grafts. Eur. J. Vasc. Surg. (1991) 5:397-405.
55. GIMBRONE MJ: Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am. J. Cardiol. (1995) 75:B67-B70.
56. HEDEMAN-JOOSTEN P, VERHAGEN H, HEIJNEN-SNYDER G et al.: Thrombogenesis of different cell types seeded on vascular grafts and studied under blood-flow conditions. J. Vasc. Surg. (1998) 28:1094-1103.
57. KOVEKER G, GRAHAM L, BURKEL W et al.: Extracellular matrix preparation of expanded polytetrafluoroethylene grafts seeded with endothelial cells: influence on early platelet deposition, cellular growth, and luminal prostacyclin release. Surgery (1991) 109:313-319.
58. NIEBAUER J, SCHWARZACHER S, HAYASE M et al.: Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis. Circulation (1999) 100:1830-1835.
59. CLOWES A, CLOWES M, REIDY M: Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels. Lab. Invest. (1986) 54:295-303.
60. JANSSENS S, FLAHERTY D, NONG Z et al.: Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation (1998) 97:1274-1281.
61. EDELMAN E, ADAMS D, KARNOVSKY M: Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. USA (1990) 87:3773-3777.
62. HERRING M, BAUGHMAN S, GLOVER J: Endothelium develops on seeded human arterial prosthesis: a brief clinical note. J. Vasc. Surg. (1985) 2:727-730.
63. HERRING M, COMPTON R, LEGRAND D et al.: Endothelial seeding of polytetrafluoroethylene popliteal bypasses. A preliminary report. J. Vasc. Surg. (1987) 6:114-118.
64. ZILLA P, DEUTSCH M, MEINHART J et al.: Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J. Vasc. Surg. (1994) 19:540-548.
65. MEINHART J, DEUTSCH M, FISCHLEIN T et al.: Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Ann. Thorac. Surg. (2001) 71:5327-5331.
66. LESECHE G, OHAN J, BOUTTIER S et al.: Above-knee femoropopliteal bypass grafting using endothelial cell seeded PTFE grafts: five-year clinical experience. Ann. Vasc. Surg. (1995) 9(Suppl.):S15-S23.
67. MAGOMETSCHNIGG H, KADLETZ M, VODRAZKA M et al.: Prospective clinical study with in vitro endothelial cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction. J. Vasc. Surg. (1992) 15:527-535.
68. HOLLIER L, FOWL R, PENNELL R et al.: Are seeded endothelial cells the origin of neointima on prosthetic vascular grafts? J. Vasc. Surg. (1986) 3:65-73.
69. ZHANG Z, WANG Z, LIU S, KODAMA M: Pore size, tissue ingrowth, and endothelialization of small-diameter microporous polyurethane vascular prostheses. Biomaterials (2004) 25:177-187.
70. VOHRA R, THOMSON G, SHARMA H, CARR H, WALKER M: Effects of shear stress on endothelial cell monolayers on expanded polytetrafluoroethylene (ePTFE) grafts using preclot and fibronectin matrices. Eur. J. Vasc. Surg. (1990) 4:33-41.
71. SACKMAN JE, FREEMAN MB, PETERSEN MG et al.: Synthetic vascular grafts seeded with genetically modified endothelium in the dog: evaluation of the effect of seeding technique and retroviral vector on cell persistence in vivo. Cell Transplant. (1995) 4(2):219-235.
72. VOHRA R, THOMSON G, CARR H, SHARMA H, WALKER M: Comparison of different vascular prostheses and matrices in relation to endothelial seeding. Br. J. Surg. (1991) 78:417-420.
73. MEINHART J, SCHENSE J, SCHIMA H et al.: Enhanced endothelial cell retention on shear-stressed synthetic vascular grafts precoated with RGD-cross-linked fibrin. Tissue Eng. (2005) 11:887-895.
74. CHAN B, LIU W, KLITZMAN B, REICHERT W, TRUSKEY G: In vivo performance of dual ligand augmented endothelialized expanded polytetrafluoroethylene vascular grafts. J. Biomed. Mater. Res. B Appl. Biomater. (2005) 72:52-63.
75. TIWARI A, SALACINSKI H, PUNSHON G, HAMILTON G, SEIFALIAN A: Development of a hybrid cardiovascular graft using a tissue engineering approach. FASEB J. (2002) 16(8):791-796.
76. BOSIERS M, DELOOSE K, VERBIST J et al.: Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J. Vasc. Surg. (2006) 43:313-319.
77. FERNANDEZ P, DEGUETTE A, POTHUAUD L et al.: Quality control assessment of ePTFE precoating procedure for in vitro endothelial cell seeding. Biomaterials (2005) 26:5042-5047.
78. DEUTSCH M, MEINHART J, FISCHLEIN T, PREISS P, ZILLA P: Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience. Surgery (1999) 126:847-855.
79. CHENNAZHY K, KRISHNAN L: Effect of passage number and matrix characteristics on differentiation of endothelial cells cultured for tissue engineering. Biomaterials (2005) 26:5658-5667.
80. SCHNEIDER A, CHANDRA M, LAZAROVICI G et al.: Naturally produced extracellular matrix is an excellent substrate for canine endothelial cell proliferation and resistance to shear stress on PTFE vascular grafts. Thromb. Haemost. (1997) 78(5):1392-1398.
81. SCHNEIDER A, MELMED RN, SCHWALB H et al.: An improved method for endothelial cell seeding on polytetrafluoroethylene small caliber vascular grafts. J. Vasc. Surg. (1992) 15(4):649-656.
82. SCHNEIDER A, SCHWALB H, VLODAVSKY I, URETZKY G: An improved method of endothelial seeding on small caliber prosthetic vascular grafts coated with natural extracellular matrix. Clin. Mater. (1993) 13(1-4):51-55.
83. IWAMI Y, MASUDA H, ASAHARA T: Endothelial progenitor cells: past, state of the art, and future. J. Cell Mol. Med. (2004) 8:488-497.
84. ROTMANS J, HEYLIGERS J, VERHAGEN H et al: In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation (2005) 112:12-18.
85. KAUSHAL S, AMIEL G, GULESERIAN K et al.: Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med. (2001) 7:1035-1040.
86. NOISHIKI Y, TOMIZAWA Y, YAMANE Y, MATSUMOTO A: Autocrine angiogenic vascular prosthesis with bone marrow transplantation. Nat. Med. (1996) 2:90-93.
87. GULBINS H, PRITISANAC A, DAUNER M et al.: Seeding of human vascular cells onto small diameter polyurethane vascular grafts. Thorac. Cardiovasc. Surg. (2006) 54(2):102-107.
88. GULBINS H, PRITISANAC A, PIEPER K et al.: Successful endothelialization of porcine glutaraldehyde-fixed aortic valves in a heterotopic sheep model. Ann. Thorac. Surg. (2006) 81(4):1472- 1479.
89. SHEN JY, CHAN-PARK MB, HE B et al.: Three-dimensional microchannels in biodegradable polymeric films for control orientation and phenotype of vascular smooth muscle cells. Tissue Eng. (2006) 12(8):2229-2240.
90. KIM BS, NIKOLOVSKI J, BONADIO J, SMILEY E, MOONEY DJ: Engineered smooth muscle tissues: regulating cell phenotype with the scaffold. Exp. Cell Res. (1999) 251(2):318-328.
91. FLUGELMAN MY, VIRMANI R, LEON MB, BOWMAN RL, DICHEK DA: Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circ. Res. (1992) 70(2):348-354.
92. KOREN B, WEISZ A, FISCHER L et al.: Efficient transduction and seeding of human endothelial cells onto metallic stents using bicistronic pseudo-typed retroviral vectors encoding vascular endothelial growth factor. Cardiovasc. Revasc. Med. (2006) 7(3):173-178.
93. NEWMAN K, NGUYEN N, DICHEK D: Quantification of vascular graft seeding by use of computer-assisted image analysis and genetically modified endothelial cells. J. Vasc. Surg. (1991) 14:140-146.
94. DICHEK D, ANDERSON J, KELLY A, HANSON S, HARKER L: Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation (1996) 93:301-309.
95. DUNN P, NEWMAN K, JONES M et al.: Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant tpa results in decreased seeded cell retention in vitro and in vivo. Circulation (1996) 93:1439-1446.
96. FALK J, TOWNSEND LE, VOGEL LM et al.: Improved adherence of genetically modified endothelial cells to small-diameter expanded polytetrafluoroethylene grafts in a canine model. J. Vasc. Surg. (1998) 27(5):902-908; discussion 908-909.
97. KANKI-HORIMOTO S, HORIMOTO H, MIENO S et al.: Synthetic vascular prosthesis impregnated with mesenchymal stem cells overexpressing endothelial nitric oxide synthase. Circulation (2006) 114(Suppl. 1):I327-I330.
98. PREIS M, COHEN T, SARNATZKI Y et al.: Effects of fibulin-5 on attachment, adhesion, and proliferation of primary human endothelial cells. Biochem. Biophys. Res. Commun. (2006) 348:1024-1033.
99. MIDWOOD K, SCHWARZBAUER J: Elastic fibers: building bridges between cells and their matrix. Curr. Biol. (2002) 12:R279-R281.
100. LEUNG D, CACHIANES G, KUANG W, GOEDDEL D, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309.
101. MUSTONEN T, ALITALO K: Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. (1995) 129:895-898.
102. FERRARA N: Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. (2004) 25:581-611.
103. KECK P, HAUSER S, KRIVI G et al.: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (1989) 246:1309-1312.